Abstract
Prostaglandin D2 is the most abundant prostaglandin in the mammalian brain. Exposure to stressful stimuli is often accompanied by reduced pain sensitivity, termed “stress-induced analgesia” (SIA). In the present study, the possible modulatory role of prostaglandin-D2 (PGD2) in the acute or chronic type of SIA was examined in male and female rats. Acute and chronic (long-term) restraint stress (RS) in male and female rats was performed prior to intraplantar injections of formalin, a noxious inflammatory agent. The involvements of specific PGD2 receptors in the modulatory role of PGD2 on SIA also investigated by specific antagonists (DP1 or DP2). Corticosterone levels were assessed in groups of rats following exposure to stress. Acute or chronic restraint stress altered formalin-induced spontaneous behaviors in male and female rats. Furthermore, intrathecal microinjection of PGD2 (10 µg/mL) could reverse acute SIA in male but not in female rats. DP2 antagonist of PGD2 (CAY10471) attenuated pain score in the acute RS-induced analgesia in male rats. Administration of PGD2 increases the phospho-extracellular signal regulated kinase 2 (pERK2) levels in the spinal cord of male RS rats. Sex differences were also seen in plasma corticosterone concentrations post injection of PGD2 in acute SIA in male rats. The outcome suggests that not only central microinjection of PGD2 could attenuate acute SIA in male rats, but also its antagonist could turn over this effect.
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1134%2FS1819712424020119/MediaObjects/11710_2024_5327_Fig1_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1134%2FS1819712424020119/MediaObjects/11710_2024_5327_Fig2_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1134%2FS1819712424020119/MediaObjects/11710_2024_5327_Fig3_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1134%2FS1819712424020119/MediaObjects/11710_2024_5327_Fig4_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1134%2FS1819712424020119/MediaObjects/11710_2024_5327_Fig5_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1134%2FS1819712424020119/MediaObjects/11710_2024_5327_Fig6_HTML.png)
Similar content being viewed by others
REFERENCES
Butler, R.K. and Finn, D.P., Progr. Neurobiol., 2009, vol. 88, no. 3, pp. 184–202.
Hohmann, A.G., Suplita, R.L., Bolton, N.M., Neely, M.H., Fegley, D., Mangieri, R., Krey, J.F., Michael Walker, J., Holmes, P.V., and Crystal, J.D., Nature, 2005, vol. 435, no. 7045, pp. 1108–1112.
Thomson, J.S., Deakin, A.G., Cossins, A.R., Spencer, J.W., Young, I.S., and Sneddon, L.U., J. Exp. Biol., 2020, vol. 223, no. 14, p. jeb224527.
Crettaz, B., Marziniak, M., Willeke, P., Young, P., Hellhammer, D., Stumpf, A., and Burgmer, M., PLoS One, 2013, vol. 8, no. 8, p. e69460.
Ma, W., Li, L. and **ng, S., Brain Res., 2019, vol. 1721, p. 146335.
Bhattacharya, S.K., Keshary, P.R., and Sanyal, A.K., Eur. J. Pharmacol., 1978, vol. 50, no. 1, pp. 83–85.
Furuyashiki, T. and Narumiya, S., Curr. Opin. Pharmacol., 2009, vol. 9, no. 1, pp. 31–38.
Yin, W., Swanson, S.P., Biltz, R.G., Goodman, E.J., Gallagher, N.R., Sheridan, J.F., and Godbout, J.P., Neuropsychopharmacol., 2022, pp. 1–12.
Schaible, H.-G., Ebersberger, A., and Natura, G., Arthritis Res. Ther., 2011, vol. 13, no. 2, pp. 1–8.
Horie, H., Matsuyama, T., Namba, M., Nonaka, K., and Tarui, S., Prostaglandins, Leukotrienes Med., 1983, vol. 12, no. 3, pp. 315–321.
Elshareif, N., Gavini, C.K., and Mansuy-Aubert, V., Sci. Rep., 2022, vol. 12, no. 1, pp. 1–10.
Uda, R., Horiguchi, S., Ito, S., Hyodo, M., and Hayaishi, O., Brain Res., 1990, vol. 510, no. 1, pp. 26–32.
Vanegas, H. and Schaible, H.-G., Progr. Neurobiol., 2001, vol. 64, no. 4, pp. 327–363.
Ebersberger, A., Natura, G., Eitner, A., Halbhuber, K.-J., Rost, R. and Schaible, H.-G., Pain, 2011, vol. 152, no. 5, pp. 1114–1126.
Imbe, H., Murakami, S., Okamoto, K., Iwai-Liao, Y., and Senba, E., Pain, 2004, vol. 112, no. 3, pp. 361–371.
Rubinfeld, H. and Seger, R., Mol. Biotechnol., 2005, vol. 31, no. 2, pp. 151–174.
Ma, J., Yang, Q., Wei, Y., Yang, Y., Ji, C., Hu, X., Mai, S., Kuang, S., Tian, X., and Luo, Y., Sci. Rep., 2016, vol. 6, no. 1, pp. 1–11.
Andreeva, L. and Rang, H., Brit. J. Pharmacol., 1993, vol. 108, no. 1, pp. 185–190.
Ohkubo, T., Shibata, M., Takahashi, H., and Inoki, R., Japan. J. Pharmacol., 1983, vol. 33, no. 1, pp. 264–266.
Bhattacharya, S., Rao, P.M., and Gupta, G.D., J. Pharm. Pharmacol., 1989, vol. 41, no. 8, pp. 569–571.
Mohammadi, S., Oryan, S., Komaki, A., Eidi, A., and Zarei, M., Int. J. Peptide Res. Ther., 2020, vol. 26, no. 1, pp. 357–367.
Mohammadi, S. and Golshani, Y., J. Adv. Neurosci. Res., 2017, vol. 4, no. 2, pp. 30–37.
Torres, I.L.S., Buffon, A., Silveira, P.P., Duarte, M.Z., Bassani, M.G., Oliveira, S.S., Battastini, A.M.O., Sarkis, J.J., Dalmaz, C., and Ferreira, M.B.C., Physiol. Behav., 2002, vol. 75, nos. 1–2, pp. 1–5.
Dubuisson, D. and Dennis, S.G., Pain, 1978, vol. 4, pp. 161–174.
Fallahzadeh, A.R., Zarei, M., and Mohammadi, S., Entomol. Appl. Sci. Lett., 2016, vol. 3, no. 5, pp. 140–147.
Sadler, K.E., Stratton, J.M., DeBerry, J.J., and Kolber, B.J., PLoS One, 2013, vol. 8, no. 11, pp. e79617.
Mahmoodi, M., Mohammadi, S. and Enayati, F., SSU J., 2016, vol. 24, no. 3, pp. 201–210.
Ahmadimoghaddam, D., Sadeghian, R., Ranjbar, A., Izadidastenaei, Z., and Mohammadi, S., Res. Pharm. Sci., 2020, vol. 15, no. 5, p. 463.
Golshani, Y. and Mohammadi, S., Armaghane Danesh, 2015, vol. 19, no. 12, pp. 1058–1068.
Long, C.C., Sadler, K.E., and Kolber, B.J., Physiol. Behav., 2016, vol. 165, no., pp. 278–285.
Vendruscolo, L.F., Pamplona, F.A., and Takahashi, R.N., Brain Res., 2004, vol. 1030, no. 2, pp. 277–283.
Giles, H. and Leff, P., Prostaglandins, 1988, vol. 35, no. 2, pp. 277–300.
Minami, T., Okuda-Ashitaka, E., Mori, H., Ito, S., and Hayaishi, O., J. Pharmacol. Exp. Ther., 1996, vol. 278, no. 3, pp. 1146–1152.
Kanda, H., Kobayashi, K., Yamanaka, H., and Noguchi, K., Glia, 2013, vol. 61, no. 6, pp. 943–956.
McEwen, B.S. and Kalia, M., Metabolism, 2010, vol. 59, pp. S9–S15.
Atmaramani, R.R., Black, B.J., de la Peña, J.B., Campbell, Z.T., and Pancrazio, J.J., Bioengineering, 2020, vol. 7, no. 2, p. 44.
Ji, R.-R., Baba, H., Brenner, G.J., and Woolf, C.J., Nat. Neurosci., 1999, vol. 2, no. 12, pp. 1114–1119.
Guo, A.-L., Petraglia, F., Criscuolo, M., Ficarra, G., Nappi, R.E., Palumbo, M., Valentini, A., and Genazzani, A.R., Eur. J. Endocrinol., 1994, vol. 131, no. 5, pp. 535–539.
Funding
The study was funded by Vice-chancellor for Research and Technology at Hamadan University of Medical Sciences (No. 140004083033) and extracted from MSc Thesis.
Author information
Authors and Affiliations
Contributions
Data analysis and interpretation: Mona Paknia; Data acquisition, Mohammad Zarei; Study conception, design, and critical revision. Mona Paknia, Safoura Raoufi, Parisa Habibi, Fatemeh Ramezani-Aliakbari, and Seyed Asaad Karimi; Drafting of the manuscript.
Corresponding author
Ethics declarations
ETHICS APPROVAL AND CONSENT TO PARTICIPATE
The experimentation protocols were following the instructions agreed by the NIH Publication; No. 85-23, 1985. The Ethics Committee of the University of Medical Sciences- Hamadan approved the research (Ethical No. 1397.618).
CONFLICT OF INTEREST
The authors of this work declare that they have no conflicts of interest.
Additional information
Publisher’s Note.
Pleiades Publishing remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Mona Paknia, Zarei, M., Raoufi, S. et al. Effects of Intrathecal Administration of Prostaglandin-D2 on Stress-Induced Analgesia: Involvements of DP2 Receptors. Neurochem. J. 18, 313–320 (2024). https://doi.org/10.1134/S1819712424020119
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S1819712424020119